Effectiveness and cost-effectiveness of health interventions for rare cancers: evidence from a systematic literature review and meta-analysis
Providing equal access to healthcare facilities and to high quality therapeutic interventions to all cancer patients, regardless the rarity of their disease should be incontrovertible.
Yet, rare cancers seem to be as much a challenge for patients as for healthcare systems. The rare cancer market is invisible to investors as no sufficient financial data is available to provide evidence on cost effectiveness of treatments, diagnoses and follow-up care.
In October 2016, the Rare Cancer Project team started working with Dr Apostolos Tsiachristas on a systematic review(to be published in 2017) on costs of health interventions by evaluating rare cancers publications and to assess the beneficial effects of given treatments in term of health outcomes and costs reporting.